EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT)
Introduction. Overexpression of Her2/neu is detected in 15–20 % of patients with breast cancer and associated with an aggressive form of disease and low overall and disease-free survival rates. Currently, immunohistochemical studies (IHC) and methods of in situ hybridization are used to assess Her2/...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2021-10-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/1930 |
| _version_ | 1797875723129585664 |
|---|---|
| author | O. D. Bragina V. I. Chernov R. V. Zelchan A. A. Medvedeva I. G. Frolova E. A. Dudnikova V. E. Goldberg V. M. Tolmachev |
| author_facet | O. D. Bragina V. I. Chernov R. V. Zelchan A. A. Medvedeva I. G. Frolova E. A. Dudnikova V. E. Goldberg V. M. Tolmachev |
| author_sort | O. D. Bragina |
| collection | DOAJ |
| description | Introduction. Overexpression of Her2/neu is detected in 15–20 % of patients with breast cancer and associated with an aggressive form of disease and low overall and disease-free survival rates. Currently, immunohistochemical studies (IHC) and methods of in situ hybridization are used to assess Her2/neu status. One of significant drawbacks of this detection is the impossibility of simultaneous assessment of the receptor status of the primary tumor and metastatic sites. The increasing popularity of radionuclide methods using recombinant proteins as a targeting module have already demonstrated their effectiveness in solving this question at the initial stages of clinical research.The purpose of this study is to demonstrate a clinical case of assessing the extent of breast cancer in a patient with overexpression of Her2/neu using a radiopharmaceutical based on targeted protein molecules labeled with technetium-99m.Description of the clinical case. A patient diagnosed with stage IIIA right breast cancer (T2N2M0), multicentric growth and metastases in right axillary and subclavian lymph nodes at the diagnostic stage was injected intravenously with 99mTc-ADAPT6 radiopharmaceutical. The drug was prepared in the Department of Nuclear Medicine of Research Cancer Institute (Tomsk) immediately before its administration. Planar scintigraphy and singlephoton emission tomography of the chest organs were performed 2 hours after injection of 99mTc-ADAPT6 radiopharmaceutical. In addition to the previously described tumors, 3 foci of hyperfixation of the tracer in the projection of the 5th rib on the right along the middle-clavicular line, as well as in the projection of the 8 and 9 thoracic vertebrae (Th VIII, IX) were found. Computed tomography of the chest organs and bone scintigraphy with 99mTc-pyrophosphate showed no metastases in the 5th rib on the right and Th VIII, IX. Magnetic resonance imaging of the thoracic spine revealed 2 metastatic foci in Th VIII, IX. Planar scintigraphy with 99mTc-pyrophosphate and CT performed 6 months after injection of 99mTc-ADAPT6 revealed previously described foci in the projection of the thoracic spine (Th VIII, IX) and 5 ribs on the right along the mid-clavicular line. Conclusion. The results demonstrated during the study suggest that 99mTc-ADAPT6 is a promising tracer for molecular imaging of tumor foci with overexpression of the Her2/neu receptor in breast cancer patients. |
| first_indexed | 2024-04-10T01:52:09Z |
| format | Article |
| id | doaj.art-6067b0f18a2c457198316e0e0a90facc |
| institution | Directory Open Access Journal |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| last_indexed | 2024-04-10T01:52:09Z |
| publishDate | 2021-10-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj.art-6067b0f18a2c457198316e0e0a90facc2023-03-13T09:05:55ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682021-10-0120517017810.21294/1814-4861-2021-20-5-170-178914EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT)O. D. Bragina0V. I. Chernov1R. V. Zelchan2A. A. Medvedeva3I. G. Frolova4E. A. Dudnikova5V. E. Goldberg6V. M. Tolmachev7Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; Национальный исследовательский Томский политехнический университет, НИЦ «Онкотераностика»Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; Национальный исследовательский Томский политехнический университет, НИЦ «Онкотераностика»Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; Национальный исследовательский Томский политехнический университет, НИЦ «Онкотераностика»Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукНациональный исследовательский Томский политехнический университет, НИЦ «Онкотераностика»; Уппсальский университетIntroduction. Overexpression of Her2/neu is detected in 15–20 % of patients with breast cancer and associated with an aggressive form of disease and low overall and disease-free survival rates. Currently, immunohistochemical studies (IHC) and methods of in situ hybridization are used to assess Her2/neu status. One of significant drawbacks of this detection is the impossibility of simultaneous assessment of the receptor status of the primary tumor and metastatic sites. The increasing popularity of radionuclide methods using recombinant proteins as a targeting module have already demonstrated their effectiveness in solving this question at the initial stages of clinical research.The purpose of this study is to demonstrate a clinical case of assessing the extent of breast cancer in a patient with overexpression of Her2/neu using a radiopharmaceutical based on targeted protein molecules labeled with technetium-99m.Description of the clinical case. A patient diagnosed with stage IIIA right breast cancer (T2N2M0), multicentric growth and metastases in right axillary and subclavian lymph nodes at the diagnostic stage was injected intravenously with 99mTc-ADAPT6 radiopharmaceutical. The drug was prepared in the Department of Nuclear Medicine of Research Cancer Institute (Tomsk) immediately before its administration. Planar scintigraphy and singlephoton emission tomography of the chest organs were performed 2 hours after injection of 99mTc-ADAPT6 radiopharmaceutical. In addition to the previously described tumors, 3 foci of hyperfixation of the tracer in the projection of the 5th rib on the right along the middle-clavicular line, as well as in the projection of the 8 and 9 thoracic vertebrae (Th VIII, IX) were found. Computed tomography of the chest organs and bone scintigraphy with 99mTc-pyrophosphate showed no metastases in the 5th rib on the right and Th VIII, IX. Magnetic resonance imaging of the thoracic spine revealed 2 metastatic foci in Th VIII, IX. Planar scintigraphy with 99mTc-pyrophosphate and CT performed 6 months after injection of 99mTc-ADAPT6 revealed previously described foci in the projection of the thoracic spine (Th VIII, IX) and 5 ribs on the right along the mid-clavicular line. Conclusion. The results demonstrated during the study suggest that 99mTc-ADAPT6 is a promising tracer for molecular imaging of tumor foci with overexpression of the Her2/neu receptor in breast cancer patients.https://www.siboncoj.ru/jour/article/view/1930рак молочной железырецептор эпидермального фактора роста her2/neuмолекулярная визуализацияальтернативные каркасные белки |
| spellingShingle | O. D. Bragina V. I. Chernov R. V. Zelchan A. A. Medvedeva I. G. Frolova E. A. Dudnikova V. E. Goldberg V. M. Tolmachev EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT) Сибирский онкологический журнал рак молочной железы рецептор эпидермального фактора роста her2/neu молекулярная визуализация альтернативные каркасные белки |
| title | EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT) |
| title_full | EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT) |
| title_fullStr | EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT) |
| title_full_unstemmed | EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT) |
| title_short | EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT) |
| title_sort | evaluation of extent of breast cancer in a patient with her2 neu overexpression using a radiopharmaceutical based on technetium 99m labeled target molecules case report |
| topic | рак молочной железы рецептор эпидермального фактора роста her2/neu молекулярная визуализация альтернативные каркасные белки |
| url | https://www.siboncoj.ru/jour/article/view/1930 |
| work_keys_str_mv | AT odbragina evaluationofextentofbreastcancerinapatientwithher2neuoverexpressionusingaradiopharmaceuticalbasedontechnetium99mlabeledtargetmoleculescasereport AT vichernov evaluationofextentofbreastcancerinapatientwithher2neuoverexpressionusingaradiopharmaceuticalbasedontechnetium99mlabeledtargetmoleculescasereport AT rvzelchan evaluationofextentofbreastcancerinapatientwithher2neuoverexpressionusingaradiopharmaceuticalbasedontechnetium99mlabeledtargetmoleculescasereport AT aamedvedeva evaluationofextentofbreastcancerinapatientwithher2neuoverexpressionusingaradiopharmaceuticalbasedontechnetium99mlabeledtargetmoleculescasereport AT igfrolova evaluationofextentofbreastcancerinapatientwithher2neuoverexpressionusingaradiopharmaceuticalbasedontechnetium99mlabeledtargetmoleculescasereport AT eadudnikova evaluationofextentofbreastcancerinapatientwithher2neuoverexpressionusingaradiopharmaceuticalbasedontechnetium99mlabeledtargetmoleculescasereport AT vegoldberg evaluationofextentofbreastcancerinapatientwithher2neuoverexpressionusingaradiopharmaceuticalbasedontechnetium99mlabeledtargetmoleculescasereport AT vmtolmachev evaluationofextentofbreastcancerinapatientwithher2neuoverexpressionusingaradiopharmaceuticalbasedontechnetium99mlabeledtargetmoleculescasereport |